Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aminoglycosides + β-lactams is a combination of two classes of antibiotics frequently used together for the treatment of severe bacterial infections, particularly those caused by Gram-negative organisms. Aminoglycosides (such as gentamicin, tobramycin, or amikacin) act primarily by binding to the 30S ribosomal subunit and inhibiting bacterial protein synthesis, leading to bactericidal activity. They also disrupt the outer membrane of bacteria, increasing permeability. β-Lactams (such as penicillins or cephalosporins) inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), resulting in cell lysis and death. The combination is often synergistic because β-lactams can increase aminoglycoside uptake into bacteria by disrupting the cell wall. This regimen is commonly used for serious infections like endocarditis and sepsis due to Enterococcus species or other resistant Gram-negative pathogens[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aminoglycosides + β-lactams.